Contineum Therapeutics

Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oral small-molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications with significant unmet needs. Contineum targets biological pathways associated with specific clinical disabilities, which, once modulated, can significantly impact disease progression. The company has a range of internally developed programs for treating various NI&I diseases, including PIPE-791, an LPA1 receptor antagonist for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PMS), and PIPE-307, a selective M1 receptor inhibitor for relapsing-remitting multiple sclerosis (RRMS) currently in Phase 2, as well as a Phase 2 selective M1 receptor inhibitor for treating depression.